Literature DB >> 29255947

Pre-aggregation kinetics and intermediates of α-synuclein monitored by the ESIPT probe 7MFE.

Jonathan A Fauerbach1, Thomas M Jovin2.   

Abstract

The defining n class="Chemical">feature of the extensive family of amyloid diseases is the formation of networks of entangled elongated protein fibrils and amorphous aggregates exhibiting crossed β-sheet secondary structure. The time course of amyloid conversion has been studied extensively in vitro with the proteins involved in the neurodegenerative pathology of Parkinson's disease (α-synuclein), Alzheimer's disease (Tau) and Huntington's disease (Huntingtin). Although much is known about the thermodynamics and kinetics of the transition from a soluble, intrinsically disordered monomer to the fibrillar end state, the putative oligomeric intermediates, currently considered to be the major initiators of cellular toxicity, are as yet poorly defined. We have detected and characterized amyloid precursors by monitoring AS aggregation with ESIPT (excited state intramolecular protein transfer) probes, one of which, 7MFE [7-(3-maleimido-N-propanamide)-2-(4-diethyaminophenyl)-3-hydroxychromone], is introduced here and compared with a related compound, 6MFC, used previously. A series of 140 spectra for sparsely labeled AS was acquired during the course of aggregation, and resolved into the relative contributions (spectra, intensities) of discrete molecular species including the monomeric, fibrillar, and ensemble of intermediate forms. Based on these findings, a kinetic scheme was devised to simulate progress curves as a function of key parameters. An essential feature of the model, one not previously invoked in schemes of amyloid aggregation, is the catalysis of molecular fuzziness by discrete colloidal nanoparticles arising spontaneously via monomer condensation upon exposure of AS to ≥ 37 °C.

Entities:  

Keywords:  3-Hydroxychromones; Aggregation kinetics; Amyloid; MFC; Oligomers; Supramolecular intermediates

Mesh:

Substances:

Year:  2017        PMID: 29255947      PMCID: PMC5982440          DOI: 10.1007/s00249-017-1272-0

Source DB:  PubMed          Journal:  Eur Biophys J        ISSN: 0175-7571            Impact factor:   1.733


  63 in total

1.  Atomistic theory of amyloid fibril nucleation.

Authors:  Raffaela Cabriolu; Dimo Kashchiev; Stefan Auer
Journal:  J Chem Phys       Date:  2010-12-14       Impact factor: 3.488

2.  Aggregation of α-synuclein is kinetically controlled by intramolecular diffusion.

Authors:  Basir Ahmad; Yujie Chen; Lisa J Lapidus
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

Review 3.  Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.

Authors:  Emily M Rocha; Briana De Miranda; Laurie H Sanders
Journal:  Neurobiol Dis       Date:  2017-04-08       Impact factor: 5.996

4.  Fluorescent ratiometric MFC probe sensitive to early stages of alpha-synuclein aggregation.

Authors:  Dmytro A Yushchenko; Jonathan A Fauerbach; Shyamala Thirunavukkuarasu; Elizabeth A Jares-Erijman; Thomas M Jovin
Journal:  J Am Chem Soc       Date:  2010-06-16       Impact factor: 15.419

5.  Attenuation of the early events of α-synuclein aggregation: a fluorescence correlation spectroscopy and laser scanning microscopy study in the presence of surface-coated Fe3O4 nanoparticles.

Authors:  Nidhi Joshi; Sujit Basak; Sangeeta Kundu; Goutam De; Anindita Mukhopadhyay; Krishnananda Chattopadhyay
Journal:  Langmuir       Date:  2015-01-20       Impact factor: 3.882

6.  The effect of fluorescent labeling on α-synuclein fibril morphology.

Authors:  M Mučibabić; M M Apetri; G W Canters; T J Aartsma
Journal:  Biochim Biophys Acta       Date:  2016-07-28

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

8.  Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.

Authors:  Lena F Burbulla; Pingping Song; Joseph R Mazzulli; Enrico Zampese; Yvette C Wong; Sohee Jeon; David P Santos; Judith Blanz; Carolin D Obermaier; Chelsee Strojny; Jeffrey N Savas; Evangelos Kiskinis; Xiaoxi Zhuang; Rejko Krüger; D James Surmeier; Dimitri Krainc
Journal:  Science       Date:  2017-09-07       Impact factor: 47.728

9.  Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species.

Authors:  Florencia González-Lizárraga; Sergio B Socías; César L Ávila; Clarisa M Torres-Bugeau; Leandro R S Barbosa; Andres Binolfi; Julia E Sepúlveda-Díaz; Elaine Del-Bel; Claudio O Fernandez; Dulce Papy-Garcia; Rosangela Itri; Rita Raisman-Vozari; Rosana N Chehín
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

10.  Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation.

Authors:  Alexander K Buell; Céline Galvagnion; Ricardo Gaspar; Emma Sparr; Michele Vendruscolo; Tuomas P J Knowles; Sara Linse; Christopher M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

View more
  4 in total

Review 1.  New strategies for fluorescently labeling proteins in the study of amyloids.

Authors:  Marie Shimogawa; E James Petersson
Journal:  Curr Opin Chem Biol       Date:  2021-06-03       Impact factor: 8.972

Review 2.  High-Speed Atomic Force Microscopy Reveals the Structural Dynamics of the Amyloid-β and Amylin Aggregation Pathways.

Authors:  Takahiro Watanabe-Nakayama; Bikash R Sahoo; Ayyalusamy Ramamoorthy; Kenjiro Ono
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

Review 3.  CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.

Authors:  Tirthankar Sen; Rajkumar P Thummer
Journal:  Neurotox Res       Date:  2022-08-31       Impact factor: 3.978

4.  Modulation of α-Synuclein Aggregation In Vitro by a DNA Aptamer.

Authors:  Claire H Tran; Ranajay Saha; Celia Blanco; Damayanti Bagchi; Irene A Chen
Journal:  Biochemistry       Date:  2022-08-22       Impact factor: 3.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.